• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by CareDx Inc.

    6/11/25 4:20:36 PM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001042875
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    CAREDX, INC.
    SEC File Number
    001-36536
    Address of Issuer
    8000 Marina Boulevard, 4th Floor
    Brisbane
    CALIFORNIA
    94005
    Phone
    415-287-2300
    Name of Person for Whose Account the Securities are To Be Sold
    WILLIAM HAGSTROM
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    19391385917.745568054906/11/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/11/2025Stock Option ExerciseIssuerCheckbox not checked1939106/11/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    William Hagstrom
    8000 Marina Boulevard, 4th Floor
    Brisbane � CA � 94005
    Common05/28/202530000523413.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/11/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ William Arthur Hagstrom

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CDNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    8/15/2023$12.00Mkt Perform → Outperform
    Raymond James
    5/11/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Maag Peter sold $192,420 worth of shares (10,000 units at $19.24), decreasing direct ownership by 3% to 318,846 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      6/20/25 4:30:13 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Director Goldberg Michael was granted 12,103 shares, increasing direct ownership by 9% to 152,998 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      6/17/25 4:56:07 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Director Cohen Fred E was granted 12,103 shares, increasing direct ownership by 8% to 155,265 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      6/17/25 4:35:09 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    SEC Filings

    See more
    • CareDx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CareDx, Inc. (0001217234) (Filer)

      6/12/25 4:32:37 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by CareDx Inc.

      144 - CareDx, Inc. (0001217234) (Subject)

      6/11/25 4:20:36 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - CareDx, Inc. (0001217234) (Filer)

      6/3/25 4:30:13 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CareDx Announces Repurchase of 5% of Outstanding Shares

      Board of Directors Authorizes New $50 Million Share Repurchase Program CareDx, Inc. (NASDAQ:CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock representing approximately 5% of outstanding shares. The share repurchase follows the completion of the company's seventh consecutive quarter of testing services volume growth and a first-quarter total revenue of $84.7 million, representing 18% year-over-year growth. CareDx ended

      6/3/25 4:30:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports First Quarter 2025 Results

      First Quarter Revenue of $84.7 Million, Increased 18% Year-Over-Year Grew Testing Services Volume to Approximately 47,100, Marking Seventh Consecutive Quarter of Sequential Testing Services Volume Growth CareDx, Inc. (NASDAQ:CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of $84.7 million, increased 18% year-over-year Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100, increased 12% year-over-year GAAP net loss of $10.4 million, non-GAAP net income of $5.4 million, and positive adjusted EBITDA of $4.6 million,

      4/30/25 4:05:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ ("CareDx" or the "Company")— a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 7, 2025, CareDx granted to Jennifer Foley, the Company's newly appointed Chief Product Officer, certain stock awards as an inducement material to Ms. Foley's employment with CareDx. CareDx granted Ms. Foley 36,231 restricted stock units ("RSUs") pursuant to the Company's 2016 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Company's Board o

      4/21/25 4:01:00 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CareDx upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously

      1/15/25 7:29:19 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • Wells Fargo initiated coverage on CareDx with a new price target

      Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00

      8/28/24 7:38:28 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx upgraded by BTIG Research with a new price target

      BTIG Research upgraded CareDx from Neutral to Buy and set a new price target of $40.00

      8/19/24 8:49:21 AM ET
      $CDNA
      Medical Specialities
      Health Care